Dirk Pollet
Chief Executive Officer at Enzyre BV
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Guido Maertens | M | - |
Enzyre BV
Enzyre BV Packaged SoftwareTechnology Services Enzyre BV develops biochip platform that enzymatic reactions can be measured. The company is headquartered in Nijmegen, the Netherlands. | - |
Stephan Reynier | M | 55 | 13 years | |
Jan Groen | M | 65 |
Cergentis BV
Cergentis BV Miscellaneous Commercial ServicesCommercial Services Part of Solvias AG, Cergentis BV is a Dutch genomics company that develops and commercializes TLA-based diagnostic kits for targeted complete next-generation sequencing of (trans) genes and gene editing events. The company is based in Utrecht, Netherlands. The company also provides commercial services for leading research institutes and pharmaceutical companies worldwide. The company was founded in 2012. Joris Schuurmans has been the CEO of the company since 2020. Cergentis was acquired by Solvias AG on July 12, 2022. | - |
Joris Schuurmans | M | - |
Cergentis BV
Cergentis BV Miscellaneous Commercial ServicesCommercial Services Part of Solvias AG, Cergentis BV is a Dutch genomics company that develops and commercializes TLA-based diagnostic kits for targeted complete next-generation sequencing of (trans) genes and gene editing events. The company is based in Utrecht, Netherlands. The company also provides commercial services for leading research institutes and pharmaceutical companies worldwide. The company was founded in 2012. Joris Schuurmans has been the CEO of the company since 2020. Cergentis was acquired by Solvias AG on July 12, 2022. | 4 years |
Tolleiv Trimborn | M | - |
Enzyre BV
Enzyre BV Packaged SoftwareTechnology Services Enzyre BV develops biochip platform that enzymatic reactions can be measured. The company is headquartered in Nijmegen, the Netherlands. | - |
Waander van Heerde | M | - |
Enzyre BV
Enzyre BV Packaged SoftwareTechnology Services Enzyre BV develops biochip platform that enzymatic reactions can be measured. The company is headquartered in Nijmegen, the Netherlands. | 8 years |
Judith Bergboer | F | - |
Cergentis BV
Cergentis BV Miscellaneous Commercial ServicesCommercial Services Part of Solvias AG, Cergentis BV is a Dutch genomics company that develops and commercializes TLA-based diagnostic kits for targeted complete next-generation sequencing of (trans) genes and gene editing events. The company is based in Utrecht, Netherlands. The company also provides commercial services for leading research institutes and pharmaceutical companies worldwide. The company was founded in 2012. Joris Schuurmans has been the CEO of the company since 2020. Cergentis was acquired by Solvias AG on July 12, 2022. | - |
Wilm van Criekinge | M | - |
Cergentis BV
Cergentis BV Miscellaneous Commercial ServicesCommercial Services Part of Solvias AG, Cergentis BV is a Dutch genomics company that develops and commercializes TLA-based diagnostic kits for targeted complete next-generation sequencing of (trans) genes and gene editing events. The company is based in Utrecht, Netherlands. The company also provides commercial services for leading research institutes and pharmaceutical companies worldwide. The company was founded in 2012. Joris Schuurmans has been the CEO of the company since 2020. Cergentis was acquired by Solvias AG on July 12, 2022. | - |
Maja Sanders | F | - |
Cergentis BV
Cergentis BV Miscellaneous Commercial ServicesCommercial Services Part of Solvias AG, Cergentis BV is a Dutch genomics company that develops and commercializes TLA-based diagnostic kits for targeted complete next-generation sequencing of (trans) genes and gene editing events. The company is based in Utrecht, Netherlands. The company also provides commercial services for leading research institutes and pharmaceutical companies worldwide. The company was founded in 2012. Joris Schuurmans has been the CEO of the company since 2020. Cergentis was acquired by Solvias AG on July 12, 2022. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Rudi Pauwels | M | 65 |
Galapagos Genomics NV
Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma. | 3 years |
Ian Gilham | M | 64 |
Multiplicom NV
Multiplicom NV Medical SpecialtiesHealth Technology Multiplicom NV develops, manufactures, and commercializes molecular diagnostics solutions. It specializes in pathology laboratories, next generation sequencing, multiplex amplification of specific targets for resequencing, genetics, assay kits, clinical laboratories, and personalized medicine. The company was founded by Chris De Jonghe in 2011 and is headquartered in Niel, Belgium. | 4 years |
Onno van de Stolpe | M | 64 |
Galapagos Genomics NV
Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma. | 9 years |
Vicky Gwosdz | F | - |
Galapagos Genomics NV
Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma. | 4 years |
Graham Dixon | M | 63 |
Galapagos Genomics NV
Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma. | - |
Andrea Grant | M | 52 |
Galapagos Genomics NV
Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma. | - |
Pierre Schwich | M | - | - | |
Staf van Reet | M | - |
Galapagos Genomics NV
Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma. | - |
Rudy Dekeyser | M | 63 |
Multiplicom NV
Multiplicom NV Medical SpecialtiesHealth Technology Multiplicom NV develops, manufactures, and commercializes molecular diagnostics solutions. It specializes in pathology laboratories, next generation sequencing, multiplex amplification of specific targets for resequencing, genetics, assay kits, clinical laboratories, and personalized medicine. The company was founded by Chris De Jonghe in 2011 and is headquartered in Niel, Belgium. | 2 years |
Sylvie Delassus | M | - | - | |
Luc Mathis | M | - | 4 years | |
Julia Berretta | M | 43 | - |
Statistics
Country | Connections | % of total |
---|---|---|
Belgium | 8 | 38.10% |
Netherlands | 8 | 38.10% |
France | 5 | 23.81% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Dirk Pollet
- Personal Network